NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory

CONFIDENTIAL

Demo Report

Report Issued 04/02/2020 12:08

To: **88888**
Forensic Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 8051TI-POS
Patient ID 8051TI-POS
Chain 20000786
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 20000786

Positive Findings:

Compound	Result	Units	Matrix Source
Ethanol	**340**	**mg/100 g**	**002 - Abdominal**
Alprazolam	**200**	**ng/g**	**002 - Abdominal**
Delta-9 THC	**200**	**ng/g**	**002 - Abdominal**
Cocaine	**200**	**ng/g**	**002 - Abdominal**
Fentanyl	**100**	**ng/g**	**002 - Abdominal**

See Detailed Findings section for additional information

Testing Requested:

Analysis Code	Description
8051TI	Postmortem, Basic, Tissue (Forensic)

Specimens Received:

ID	Tube/Container	Volume/ Mass	Collection Date/Time	Matrix Source	Miscellaneous Information
001	Clear vial	Not Given	Not Given	Abdominal	
002	Clear vial	Not Given	Not Given	Abdominal	

All sample volumes/weights are approximations.

Specimens received on 03/31/2020.

Detailed Findings:

Analysis and Comments	Result	Units	Rpt. Limit	Specimen Source	Analysis By
Ethanol	340	mg/100 g	40	002 - Abdominal	Headspace GC
Alprazolam	200	ng/g	20	002 - Abdominal	LC-MS/MS
Delta-9 THC	200	ng/g	2.0	002 - Abdominal	LC-MS/MS
Cocaine	200	ng/g	80	002 - Abdominal	GC/MS
Ethanol	Confirmed	mg/100 g	40	002 - Abdominal	Headspace GC
Fentanyl	100	ng/g	2.0	002 - Abdominal	LC-MS/MS

Other than the above findings, examination of the specimen(s) submitted did not reveal any positive findings of toxicological significance by procedures outlined in the accompanying Analysis Summary.

Reference Comments:

1. Alprazolam (Xanax®) - Abdominal:

   Alprazolam is a DEA Schedule IV second-generation benzodiazepine, which is effective at very low doses. It shares the actions of other benzodiazepines in the management of anxiety disorders and short-term relief of anxiety associated with depressive symptoms. Alpha-hydroxyalprazolam is an active metabolite of alprazolam. Common CNS-depressant side effects of alprazolam include drowsiness and fatigue. For anxiety, daily doses of 0.8 to 4 mg are effective whereas for phobic and panic disorders, 6 to 9 mg daily is recommended.

2. Cocaine - Abdominal:

   Cocaine is a DEA Schedule II controlled central nervous stimulant drug. Effects following cocaine use can include euphoria, excitement, restlessness, risk taking, sleep disturbance, and aggression. A period of mental and physical fatigue and somnolence follow the use of cocaine after the excitant-stimulant effects wear off. Cocaine is metabolized to the inactive compounds benzoylecgonine, ecgonine methyl ester, and ecgonine. Benzoylecgonine and ecgonine methyl ester can form from cocaine breakdown after death and even after sample collection. (See also Benzoylecgonine).

3. Delta-9 THC (Active Ingredient of Marijuana) - Abdominal:

   Delta-9-THC is the principle psychoactive ingredient of marijuana/hashish. Delta-9-carboxy-THC (THCC) is the inactive metabolite of THC.

4. Ethanol (Ethyl Alcohol; Metabolite of Ethyl Acetate) - Abdominal:

   Ethyl alcohol (ethanol, drinking alcohol) is a central nervous system depressant and can cause effects such as impaired judgment, reduced alertness and impaired muscular coordination. Ethanol can also be a product of decomposition or degradation of biological samples.

5. Fentanyl (Duragesic®; Sublimaze®) - Abdominal:

   Fentanyl is a DEA Schedule II synthetic morphine substitute anesthetic/analgesic. It is reported to be 80 to 200 times as potent as morphine and has a rapid onset of action as well as addictive properties.

   Signs associated with fentanyl toxicity include severe respiratory depression, seizures, hypotension, coma and death.

   Substance(s) known to interfere with the identity and/or quantity of the reported result: 4-methylphenethyl acetyl fentanyl

Sample Comments:

001 Tissue specimen required homogenization: 20000786-001

002 NMS Labs generated homogenized Tissue sample: 20000786-002

Analysis Summary and Reporting Limits:

All of the following tests were performed for this case. For each test, the compounds listed were included in the scope. The Reporting Limit listed for each compound represents the lowest concentration of the compound that will be reported as being positive. If the compound is listed as None Detected, it is not present above the Reporting Limit. Please refer to the Positive Findings section of the report for those compounds that were identified as being present.

Acode 50012TI - Benzodiazepines Confirmation, Tissue - Abdominal

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

Compound	Rpt. Limit	Compound	Rpt. Limit
7-Amino Clonazepam	20 ng/g	Flurazepam	8.0 ng/g
Alpha-Hydroxyalprazolam	20 ng/g	Hydroxyethylflurazepam	20 ng/g
Alprazolam	20 ng/g	Hydroxytriazolam	20 ng/g
Chlordiazepoxide	80 ng/g	Lorazepam	20 ng/g
Clobazam	80 ng/g	Midazolam	20 ng/g
Clonazepam	8.0 ng/g	Nordiazepam	80 ng/g
Desalkylflurazepam	20 ng/g	Oxazepam	80 ng/g
Diazepam	80 ng/g	Temazepam	80 ng/g
Estazolam	20 ng/g	Triazolam	8.0 ng/g

Acode 50013TI - Cannabinoids Confirmation, Tissue - Abdominal

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

Compound	Rpt. Limit	Compound	Rpt. Limit
11-Hydroxy Delta-9 THC	4.0 ng/g	Delta-9 THC	2.0 ng/g
Delta-9 Carboxy THC	20 ng/g		

Acode 50014TI - Cocaine and Metabolites Confirmation, Tissue - Abdominal

-Analysis by Gas Chromatography/Mass Spectrometry (GC/MS) for:

Compound	Rpt. Limit	Compound	Rpt. Limit
Benzoylecgonine	200 ng/g	Cocaine	80 ng/g
Cocaethylene	80 ng/g		

Acode 52250TI - Alcohols and Acetone Confirmation, Tissue - Abdominal

-Analysis by Headspace Gas Chromatography (GC) for:

Compound	Rpt. Limit	Compound	Rpt. Limit
Acetone	20 mg/100 g	Isopropanol	20 mg/100 g
Ethanol	40 mg/100 g	Methanol	20 mg/100 g

Acode 52484TI - Fentanyl and Acetyl Fentanyl Confirmation, Tissue - Abdominal

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

Compound	Rpt. Limit	Compound	Rpt. Limit
Acetyl Fentanyl	2.0 ng/g	Norfentanyl	4.0 ng/g
Fentanyl	2.0 ng/g		

Acode 8051TI - Postmortem, Basic, Tissue (Forensic) - Abdominal

-Analysis by Enzyme-Linked Immunosorbent Assay (ELISA) for:

Compound	Rpt. Limit	Compound	Rpt. Limit
Amphetamines	80 ng/g	Benzodiazepines	400 ng/g
Barbiturates	0.16 mcg/g	Buprenorphine / Metabolite	2.0 ng/g

Analysis Summary and Reporting Limits:

Compound	Rpt. Limit	Compound	Rpt. Limit
Cannabinoids	40 ng/g	Methamphetamine / MDMA	80 ng/g
Cocaine / Metabolites	80 ng/g	Opiates	80 ng/g
Fentanyl / Acetyl Fentanyl	1.0 ng/g	Oxycodone / Oxymorphone	40 ng/g
Methadone / Metabolite	100 ng/g	Phencyclidine	40 ng/g

-Analysis by Headspace Gas Chromatography (GC) for:

Compound	Rpt. Limit	Compound	Rpt. Limit
Acetone	20 mg/100 g	Isopropanol	20 mg/100 g
Ethanol	40 mg/100 g	Methanol	20 mg/100 g